Introduction
The product of the cJun proto-oncogene, a member of the AP1 transcription factor family, forms homodimic and heterodimeric complexes with other members of the AP1-and ATF-transcription factor families, which regulate transcription of a variety of target genes (Benbrook and Jones, 1990; Ivashkiv et al., 1990; Hai and Curran, 1991) . Expression of c-jun is induced in response to various stimuli, including growth factors (Ryseck et al., 1988; Quantin and Breathnach, 1988) , cytokines (Brenner et al., 1989) , transforming oncogenes such as v-src, Ha-ras and E1A (van Dam et al., , 1993 Angel and Karin, 1991) , tumor promoters (like 12-O-tetradecanoylphorbol-13-acetate (TPA); Angel et al., 1988) and DNA-damaging agents (Devary et al., 1991; Stein et al., 1992; van Dam et al., 1995) . Activation of c-jun transcription by most of these agents has been shown to be mediated by two AP1/ ATF-like binding elements, designated jun1 and jun2 elements (Devary et al., 1991; Stein et al., 1992; van Dam et al., , 1993 van Dam et al., , 1995 . In vitro binding studies using extracts from various primary and transformed cell lines have shown that these elements can bind cJun/ATF2 and cJun/ATF3 heterodimers and heterodimers composed of cJun and a protein sharing homology with ATF2 (van Dam et al., 1993; Hagmeyer et al., 1996) .
The activation of the c-jun promoter through the jun1 and jun2 elements by cytokines, DNA-damaging agents and TPA appears to be mediated by posttranslational modi®cation of pre-existing Jun/ATF proteins, rather than by changes in the composition of the factors binding to the two elements (Rozek and Pfeifer, 1993; Herr et al., 1994) . Cytokines and DNAdamaging agents strongly stimulate the activity of Stress-Activated Protein Kinases (SAPK), which enhance the transactivation function of cJun and ATF2 by phosphorylation of Ser63 and Ser73 of cJun and Thr69 and Thr71 of ATF2 (Pulverer et al., 1991; Smeal et al., 1991; Franklin et al., 1992; Hibi et al., 1993; Derijard et al., 1994; Kyriakes et al., 1994; Gupta et al., 1995; Livingston et al., 1995; van Dam et al., 1995) . Activation of jun1 and jun2 elements by TPA is possibly mediated via cJun, via phosphorylation of Ser63 and Ser73 (Pulverer et al., 1991; Radler-Pohl et al., 1993) .
The E1A oncogene appears to activate the c-jun promoter by a mechanism that diers from the process of activation by TPA and DNA-damaging agents. We have shown previously that ATF2 is likely to be the main target of E1A in the activation of the c-jun promoter . In contrast to DNAdamaging agents, E1A can stimulate the transactivation function of ATF2 by a mechanism that is at least partially independent of the phosphorylation of Thr69 and Thr71 by SAPKs . In addition to its eects on ATF2, E1A may also alter the composition of the jun1-and jun2-binding factors, as is indicated by the fact that the amount of cJun/ATF3 heterodimers is increased in AdE1-transformed cells (Hagmeyer et al., 1996) .
The E1A binding proteins p300 and CBP (CREB Binding Protein) may play an important role in E1A-induced c-jun transcription since they can interact with a variety of AP1 and ATF transcription factors (Arias et al., 1994; Kwok et al., 1994; Lundblad et al., 1995; Lee et al., 1996a) . Studies on dierentiating F9 cells also indicate a role of p300 in the E1A-induced c-jun transcription (Kitabayashi et al., 1995) . The interaction between p300 and AP1/ATF proteins can be either dependent (e.g. CREB) or independent (e.g. cJun) of phosphorylation of the transcription factors (Chrivia et al., 1993; Kwok et al., 1994; . CBP can also associate with the basal transcription factor TFIIB (Kwok et al., 1994) and with the RNA polymerase II complex (Kee et al., 1996; Nakajima et al., 1997) , whereas p300 has been shown to interact either directly or indirectly with the TATA-box-binding protein (TBP) (Abraham et al., 1993) . Through their interactions with transcription factors, p300 and CBP are thought to upregulate transcription by recruiting the basal transcription apparatus to p300/CBP responsive promoters. This recruitment may indirectly be facilitated by the ability of p300 and CBP to modulate chromatin structure through their intrinsic histone acetyltransferase activity Bannister and Kouzarides, 1996) or via the p300/CBPassociated histone acetyltransferase protein P/CAF (Yang et al., 1996) .
In the present study we have analysed the role of p300 in c-jun transcription in more detail. We found that overexpression of p300 can enhance the activity of the c-jun promoter through the Jun/ATF-binding sites, jun1 and jun2. By using a Gal4-fusion-protein-based system, we found that overexpression of p300 eciently activated the N-terminal transactivation domain of ATF2, whereas that of cJun or ATF3 were hardly aected. Furthermore, DNA-binding studies indicated that endogenous p300/CBP(-like) proteins interact with Jun/ATF proteins bound to the jun2 element. Our ®nding that an ATF2 protein mutated at Thr69 and Thr71, inhibits the activation of the c-jun promoter by p300 strongly suggests that p300 regulates c-jun transcription by acting as a cofactor of ATF2.
Results p300 and E1A co-operatively activate the c-jun promoter via its AP1/ATF binding sites
We and others previously reported that adenovirus E1A proteins can both inhibit and activate AP1/ATFdependent gene expression by exerting dierential eects on cJun/Fos and cJun/ATF2 heterodimers Hagmeyer et al., 1994; Kitabayashi et al., 1995) . Repression of the AP1-induced collagenase and stromelysin genes by E1A is likely to involve binding of E1A to p300, which leads to inhibition of the p300 coactivator protein (van Dam et al., 1989; Dorsman et al., 1995; Lee et al., 1996a; Smits et al., 1996) . Other experimental data suggest that p300/CBP family members not only play a role in E1A-mediated repression of transcription, but also in E1A-mediated activation, e.g. of the c-jun promoter Kitabayashi et al., 1995; Duyndam et al., 1996) .
To examine the putative role of p300 in the activation of the c-jun promoter in the absence or presence of Ad5 E1A, we performed cotransfection experiments in F9 cells. As the activation of the c-jun promoter by E1A is mediated via two Jun/ATF binding sites, jun1 and jun2 van Dam et al., , 1993 Stein et al., 1992; Kitabayashi et al., 1995) , c-jun promoter constructs were used with either intact or mutated Jun/ATF2 sites. As shown in Figure 1a , overexpression of p300 stimulated the activity of the wild type c-jun promoter in a concentration-dependent manner, whereas the activity of the c-jun promoter lacking the two Jun/ATF binding Figure 1 Overexpression of p300 can stimulate the c-jun promoter via the jun1 and jun2 elements in the absence or presence of E1A. (a) F9 cells were transiently transfected with 1 mg of the indicated c-jun-luciferase reporter plasmids with 0, 1.5 or 3 mg of a CMVp300 expression vector and 1 mg of pUC18 carrier DNA. The amount of CMV promoter (3 mg) was kept constant by the addition of empty CMV expression vector. Three independent experiments gave similar results, one of which is shown. Standard deviations were 520%. (b and c) F9 cells were transiently transfected with 1 mg of the c-jun-luciferase (b) or collagenase (c) reporter plasmids together with 2.5 mg of an empty CMV expression vector or a CMVp300 expression vector, in the absence or presence of RSVcjun expression vector and dierent amounts of an expression vector encoding 12S E1A (see ®gure). The total amount of DNA was kept constant at 5 mg by the addition of pUC18 carrier DNA. Three independent experiments gave similar results. One of them is shown. Standard deviations were 520% p300 can enhance the activity of ATF2 MCA Duyndam et al sites was not aected. We next examined the regulation of the c-jun promoter by p300 in the presence of E1A. 12S E1A alone activated the c-jun promoter in a concentration-dependent manner up to about 12-fold at the highest E1A concentration (1.0 mg of expression vector, Figure 1b ), whereas p300 alone stimulated about 4.5-fold. Together, p300 and 12S E1A enhanced c-jun promoter activity considerably stronger: 53-fold at the highest 12S E1A concentration. This cooperation of p300 and E1A was dependent on the integrity of the jun1 and jun2 elements (Figure 1b) . Thus, like E1A and other types of stimuli, also p300 appears to stimulate the c-jun promoter by activating AP1/ATF transcription factors. Moreover, the results indicate that p300 and 12S E1A can functionally co-operate in the activation of the c-jun promoter. The observed cooperation between 12S E1A and p300 on the Jun/ATF binding sites of the c-jun promoter was striking in view of the reported inhibitory eect of E1A on Jun-, Fos-and ATF/ CREB-mediated transcription, for instance of the SV40-enhancer and the human collagenase promoter. Inhibition of these enhancers by E1A is likely to depend on the binding of E1A to p300/CBP family members Eckner et al., 1994; Lundblad et al., 1995; Lee et al., 1996a; Smits et al., 1996) . To exclude that these opposing eects of E1A and p300 on the c-jun and collagenase promoters were caused by dierences in cell type and/or relative E1A concentrations, we compared the eects of p300 and E1A on these two promoters in F9 cells. In agreement with our previously published data Hagmeyer et al., 1994) , 12S E1A activates the c-jun promoter but inhibits the cJun-induced collagenase promoter at the same E1A concentration (Figure 1c) . Moreover, also in F9 cells inhibition of the cJuninduced collagenase promoter by 12S E1A could be overcome by overexpression of p300 (Figure 1c, compare Smits et al., 1996) . This indicates that the cooperation of p300 and E1A in the activation of the c-jun promoter is a speci®c feature of the factors that bind to the Jun/ATF sites. p300 can enhance the transactivating potential of ATF2
The two Jun/ATF sites in the c-jun promoter bind at least three transcription factors in extracts of Adtransformed cells: cJun/ATF2, cJun/ATF3 and a heterodimer composed of cJun and a protein sharing homology with ATF2, whereas ATF2 homodimers predominate in F9 cells (van Dam et al., 1993; Hagmeyer et al., 1996; Duyndam and van Dam unpublished) . To examine which AP1 or ATF components can be activated by p300, we compared the eects of p300 on the transactivation potential of individual AP1 and ATF family members, using Gal4-fusion constructs containing the N-terminal transactivation domains of ATF2, ATF3, cJun or JunD ( Figure  2a ). It was found that p300 activates the N-terminus of ATF2 up to tenfold, whereas the activation of the Nterminus of cJun was less than ®vefold and no signi®cant activation was found of the N-termini of ATF3 or JunD (Figure 2b ). In line with the results obtained for the c-jun promoter (Figure 1b ), p300 and 12S E1A were found to activate the ATF2 N-terminus in a co-operative manner (Figure 2c ). It should be noted that this stimulatory eect of E1A and p300 on ATF2 is unlikely to involve direct binding of p300 to E1A, since similar results were obtained with a p300 mutant in which the domain interacting with E1A is deleted (p300del30, Eckner et al., 1994) (Figure 2c ).
These results suggest that the preferential target of p300 in the activation of the c-jun promoter is ATF2 cJun, JunD or ATF3 in the presence of an empty CMV expression vector (2.5 mg) or a CMVp300 expression vector (2.5 mg) and 0.5 mg of pUC18 DNA. The activation factor is the ratio between the activity of the Gal4-fusion proteins in the presence or absence of p300. Three independent experiments gave similar results. One of them is shown. Standard deviations were 520%. (c) F9 cells were transiently transfected with 1 mg of 56Gal4-E4-luciferase plasmid in the absence or presence of 1 mg of a Gal4-fusion expression vector, containing the N-terminus (N) of ATF2, together with an empty CMV expression vector (2.5 mg), a CMVp300 or a CMVp300 del30 expression vector in the absence or presence of an expression vector encoding 12S E1A (0.5 mg) and 0.5 mg of pUC18 DNA. The fold activation represents the ratio between the activity of the Gal4-ATF2 fusion protein in the presence or absence of p300 or/and 12S E1A. Three independent experiments gave similar results. One of them is shown. Standard deviations were 520% p300 can enhance the activity of ATF2 MCA Duyndam et al and that p300 does not function as a general coactivator of Jun/ATF transcription factors in F9 cells.
P300/CBP(-like) proteins form stable complexes with ATF2 in crude cell extracts
Stimulation of transcription by p300/CBP is believed to involve a direct interaction between p300/CBP and the DNA-binding transactivator, as has been demonstrated for example for the N-terminal transactivation domains of CREB, cFos and cJun (Chrivia et al., 1993; Kwok et al., 1994; Lee et al., 1996a) . To investigate whether the activation of the N-terminus of ATF2 by p300 involves a direct protein-protein interaction, we analysed the binding of p300/CBP proteins to GSTfusion proteins containing the N-terminal transactivation domains of cJun or ATF2 or the full-length ATF2 protein. As a positive control, GST-fusion proteins containing the p300/CBP-binding domain of E1A were examined in parallel. As shown in Figure 3 , only a speci®c interaction of p300/CBP proteins with E1A and with the N-terminal transactivation domain of cJun was detected in these GST pull-down assays. Thus, ATF2 does not appear to exhibit a detectable anity for p300/CBP under these experimental conditions.
The apparent lack of interaction between p300/CBP and GST-ATF2 might have several causes, e.g. the lack of sucient amounts of other associating proteins, the requirement for post-translational modi®cation of ATF2, or the fact that binding only can occur when ATF2 is bound to DNA. Therefore, we examined whether p300 family members can be detected in DNA-bound ATF2 complexes using extracts of F9 cells or adenovirus-transformed HER cells. First, we tested the eect of p300/CBP antisera on the DNAprotein complexes formed with the jun2 element of the c-jun promoter in gel retardation assays. We could not detect an eect in these assays with any of the p300/ CBP speci®c antisera used, suggesting that p300/CBP factors are not present in the retarded complexes formed by this binding site (data not shown). Since DNA-bound p300/CBP multiprotein complexes might be unstable during electrophoresis, we next performed p300, ATF2 and cJun co-immunoprecipitation assays on the DNA-bound Jun/ATF complexes. For this purpose, the DNA-bound proteins were ®rst covalently crosslinked to the 32 P-labelled DNA-element prior to precipitation in a non-stringent buer. Under these conditions only proteins are labelled that contact the DNA directly. Precipitation with cJun-, ATF2-or ATF3-speci®c antisera con®rmed the binding of cJun/ ATF2, cJun/ATF3 and of the heterodimer containing cJun and the ATF2-like protein in extracts of Adtransformed HER cells (Figure 4a ; van Dam et al., 1993; Hagmeyer et al., 1996) , although in the experiment shown the coprecipitation of ATF3 with cJun was relatively inecient. Using a p300-speci®c antiserum, we could not detect crosslinked polypeptides with an electrophoretic mobility of about 300 kD, indicating that the p300/CBP proteins do not directly contact the DNA. However, we did detect three bands around 50, 70 and 80 kD in the p300 immunoprecipitate, which comigrated with crosslinked cJun, ATF2-like and ATF2 proteins, respectively. No protein comigrating with ATF3 could be detected. In addition, a crosslinked protein of about 120 kD was precipitated. However, in contrast to the Jun and ATF2(-like) factors of 50, 70 and 80 kD, this 120 kD band was still visible when the DNA binding reactions were performed in the presence of a 100-fold excess of non-labelled jun2 competitor oligonucleotide, indicating that this protein did not interact speci®cally with the jun2 binding site. Similar results were obtained with another p300 antibody (data not shown).
In extracts of F9 cells (which lack cJun), p300 antibodies precipitated only one protein that specifically interacted with the jun2 Jun/ATF site. This crosslinked protein had a molecular weight of 80 kD and comigrated with crosslinked ATF2 (Figure 4b ). All other proteins present in the anti-p300 immunoprecipitate were also crosslinked in the presence of excess of non-labelled competitor. These data thus suggest that p300/CBP can interact with ATF2 complexes bound to DNA.
To examine whether ATF2 and p300/CBP proteins can associate in crude cell extracts in the absence of DNA, we performed sequential immunoprecipitation assays from 35 S-methionine-labelled cell lysates. Although F9 cells and Ad-transformed HER cells express endogenous ATF2 detectable by gelretardation, immunoblotting, in vivo labelling with 32 P-orthophosphate or in vitro labelling by crosslinking (Figure 4 ; van Duyndam et al., 1996 ; data not shown), de novo synthesis of endogenous ATF2 during 4 h of metabolic labelling was found to be very low. Therefore, cells were transfected with an ATF2 expression vector (compare lanes 2 in Figure 5b and c). Cell lysates made in a non-stringent buer were ®rst incubated with either the ATF2-or p300-speci®c antisera and the resulting complexes were subsequently dissociated by boiling, and reprecipitated by . Associating p300/CBP (like) proteins and p300/CBP (like) protein present in 100 mg of total lysate (lane 1) were detected by Western blot analysis using an antiserum recognizing both CBP and p300 proteins the same or dierent antisera. As shown for F9 cells in Figure 5a (lanes 1 ± 3), in addition to p300 and ATF2, a series of other proteins were found to be precipitated speci®cally with the ATF2 and p300 antisera. In the second round of immunoprecipitation only p300, ATF2 and an unknown protein of 55 kD predominate. Importantly, after disruption of the ®rst ATF2 immunocomplex, two dierent p300 antisera precipitated p300/CBP proteins (lanes 5A and 6A). The second p300 antiserum also brought down ATF2 (lane 6A), which is probably due to reformation of the ATF2-p300 containing complex during the incubation for the second round of immunoprecipitation.
A similar coprecipitation of endogenous p300 with exogenous 35 S-methionine labelled ATF2 was observed in adenovirus-transformed HER cells (data not shown). To con®rm that in these cells also the endogenous, non-labelled, ATF2 forms a complex with p300/CBP, we performed a sequential immunoprecipitation with non-transfected cells. As shown in Figure 5b , both p300 antisera indeed detected p300/ CBP (like) proteins in the ®rst ATF2-immunoprecipitate of non-transfected cells. Also note that, as in the case of F9 cells (Figure 5a ), a 55 kD protein is present in the ®rst-round ATF2 immunocomplex and is reprecipitated with the second p300 antiserum.
For the reciprocal experiment, analysis of the presence of ATF2 in p300/CBP immunocomplexes, we transfected Ad-transformed HER cells both with ATF2 and p300 expression vectors. As shown in Figure 5c , the labelled exogenous ATF2 could indeed be reprecipitated from the p300/CBP immunocomplex.
In summary, the data indicate that both in F9 cells and Ad-transformed HER cells p300/CBP (like) proteins and ATF2 are present in one multiprotein complex. This multiprotein complex speci®cally interacts in vitro with the jun2 element of the c-jun promoter. In addition to ATF2, also an as yet unknown protein of about 55 kD appears to be present in this complex as it can be precipitated by both p300-and ATF2-directed antisera.
Thr69 and Thr71 of ATF2 are not required for the interaction of ATF2 with p300
Stimulation of cJun-dependent transactivation by the p300-related coactivator CBP requires the presence of Ser63 and Ser73, which can be phosphorylated by the (stress-activated) Jun-N-terminal protein kinases (SAPK/JNKs, . In vitro binding assays demonstrated that mutation of these residues reduces the binding of cJun to CBP (Bannister et al., Immunoprecipitations with the indicated anti-sera were performed under mild-conditions (lane 1 ± 6) (see Materials and methods). 60 mg of lysate was used for immunoprecipitations with cJun, ATF2 and ATF3-speci®c antisera and 180 mg lysate was used for immunoprecipitations with non-immune and p300-directed antisera. The numbers on the left refer to the positions of molecularweight markers and are indicated in kilodaltons 1995). Since the N-terminus of ATF2 contains two SAPK-phosphorylation sites, Thr69 and Thr71 (Gupta et al., 1995; Livingston et al., 1995) , we examined whether Thr69 and Thr71 play a role in the binding of ATF2 to p300(like) proteins. For this purpose, we cotransfected E1-transformed HER cells with p300 and ATF2 or an ATF2 mutant in which Thr69 and Thr71 were replaced by alanines and compared the binding properties of the proteins in a sequential immunoprecipitation assay. The experiment shown in Figure 6 was performed with cells treated with arsenite, a potent inducer of SAPK activity (Kawasaki et al., 1996; Liu et al., 1996) . In agreement with previous ®ndings, a substantial amount of the exogenously expressed wild type ATF2 proteins migrates with a decreased mobility after induction of SAPK activity by arsenite treatment ( Figure 6 , lane 2; Gupta et al., 1995) , whereas these shifted forms are 3) . The p300 immunoprecipitate was disrupted and reprecipitated with the indicated antisera (lanes 4 ± 6). Lanes 4A ± 6A are longer exposures of lanes 4 ± 6, respectively. The numbers on the left refer to the positions of molecular-weight markers and are indicated in kilodaltons not detected in the case of the mutant ATF2 protein ( Figure 6, lane 7) , con®rming that the mobility shift depends on the phosphorylation of Thr69 and Thr71 (Gupta et al., 1995) . As can be seen in Figure 6 (lane 10A) the mutant ATF2 protein can be eciently reprecipitated from p300 immunoprecipitates. Identical results were obtained in the absence of arsenite (data not shown). These data indicate that the interaction between ATF2 and p300 (like) proteins in vivo does not require Thr69 and Thr71.
P300-dependent activation of ATF2 requires the presence of Thr69 and Thr71
The Thr69 and Thr71 residues of ATF2 have been found to be important for both basal and induced transcription activation (Kim et al., 1992; Gupta et al., 1995; Livingstone et al., 1995) . To determine whether these residues also play a role in the activation of the ATF2 N-terminus by p300, we compared the eects of p300 on the wild type Gal4-ATF2-N fusion protein and a mutated version in which Thr69 and Thr71 were replaced by alanines. As shown in Figure 7a , the replacement by alanines completely abolished activation of the Gal4-ATF2-N fusion protein by p300.
We subsequently examined the requirement of Thr69 and Thr71 in ATF2 for the activation of the c-jun promoter. As shown in Figure 7b , the basal activity of the c-jun promoter is not signi®cantly aected by overexpression of either wild type or mutant ATF2 proteins in F9 cells. This is in agreement with previous ®ndings that full length ATF2 is not active in most cell types (Flint and Jones, 1991; Abdel-Haviz et al., 1992; Green, 1990, 1994; Li and Green, 1996) . P300 activates the c-jun promoter and this activation is not aected when wild type ATF2 is coexpressed, indicating that endogenous ATF2 proteins are already present at saturating levels. In contrast, coexpression of the ATF2 mutated at Thr69 and Thr71 completely inhibits p300-induced c-jun promoter activity. (The wild type and mutant ATF2 proteins were expressed to similar levels, data not shown). Apparently, replacement of endogenous wild type ATF2 proteins by ATF2 proteins lacking threonines 69 and 71 abolishes the responsiveness of the c-jun promoter to p300 overexpression. Figure 6 Thr69 and Thr71 of ATF2 are not essential for the binding of ATF2 to p300 in crude cell extracts. E1-transformed HER cells were cotransfected with 10 mg of a CMVATF2 expression vector (lanes 1 ± 5) or 10 mg of an expression vector encoding an ATF2 mutant protein in which Thr69 and Thr71 were replaced by alanines (lanes 6 ± 10) and 10 mg of a CMVp300 expression vector and labelled for 4 h with 35 S-Methionine. Arsenite (0.1 mmol) was added for the last 30 min. Extracts were immunoprecipitated under mild conditions with the indicated antisera (lanes 1 ± 3 and 6 ± 8). The p300 immunoprecipitates were disrupted and reprecipitated with the indicated antisera (lanes 4, 5, 9 and 10). Lanes 4A, 5A, 9A and 10A are longer exposures of lanes 4, 5, 9 and 10, respectively In summary, the results presented provide strong evidence that p300 can activate the c-jun promoter by acting as a cofactor for ATF2 and that residues Thr69 and Thr71 of ATF2 are required for ATF2-dependent transactivation rather than for p300-ATF2 complex formation.
Discussion
The E1A-binding proteins p300 and CBP have been found to act as coactivators of various sequencespeci®c transcription factors, including several members of the AP1 and ATF families (Arias et al., 1994; Arany et al., 1995; Lee et al., 1996a Lee et al., , 1996b Smits et al., 1996) . In this report, we show that overexpression of p300 enhances c-jun transcription through two promoter elements, jun1 and jun2, which have been found to be binding sites for ATF2/ATF2, cJun/ATF2, cJun/ATF3 dimers and for dimers composed of cJun and ATF2-like proteins (van Dam et al., 1993; Hagmeyer et al., 1996) . When examined in F9 cells using individual Jun/ATF components fused to Gal4, overexpression of p300 leads to an ecient stimulation of the activity of the ATF2 N-terminus, a weak stimulation of the cJun N-terminus and no signi®cant activation of the JunD and ATF3 N-termini. These results suggest that ATF2 is a speci®c target of p300 and that this interaction plays a role in the activation of the c-jun promoter. In line with results of Lee et al. (1996b) obtained in Hela cells, we did not observe in F9 cells an eect of p300 on a Gal4-fusion protein containing the full-length ATF2 protein. This might be due to an improper conformation of the ATF2 transactivation domain when this fusion protein is bound to the promoter. The importance of the proper spatial position of transactivation domains for an ecient and functional binding of p300/CBP has recently been illustrated for the IFNb enhanceosome (Merika et al., 1998) . Our ®nding that overexpression of a transactivation-defective ATF2 mutant inhibits activation of the c-jun promoter by p300, suggests that upon binding to the c-jun promoter the transactivation domain of ATF2 is in the proper conformation and that p300 is able to activate the ATF2 proteins in their native form.
The mechanism of activation of AP1 and ATF transcription factors by p300/CBP has been explained by an interaction of their transactivation domain with these coactivators, thereby recruiting p300/CBP to the promoter. However, in GST-pull-down assays, ATF2 does not precipitate p300 (Figure 3) , and p300 does not precipitate in vitro translated ATF2 (data not shown). In both cases an interaction between cJun and p300 could be demonstrated. It is possible that direct interactions between ATF2 and p300/CBP proteins require posttranslational modi®cation of ATF2 proteins since by sequential immunoprecipitation analysis we were able to demonstrate that ATF2 is complexed to p300/CBP proteins in extracts of F9 cells and E1-transformed HER cells. Alternatively, the binding of ATF2 to p300 may be mediated by other proteins. Association of ATF2 with p300/CBP proteins may be undetectable in the GST pull-down assay described above, because the concentration of these auxiliary proteins in cell extracts is limiting. The fact that ATF2-p300/CBP complexes are also detected in lysates of F9 cells, suggests that the presence of cJun is not required for ATF2-p300/CBP association. However, this association may be mediated by other dimerization partners of ATF2 or may require an additional protein binding both ATF2 and p300, which stabilizes the interaction between ATF2 and p300. In this respect, it is interesting to note that a 55 kD ATF2-associating protein is reprecipitated by p300-directed antisera after disruption of ATF2 immunoprecipitates from F9 cells and E1-transformed HER cells (Figure  5a and b) . Since this protein might be a good candidate for mediating the interaction between ATF2 and p300, we are currently trying to clarify its identity. When this manuscript was in preparation, Kawasaki et al. (1998) reported the presence of p300 and ATF2 in one complex. In line with our experiments, all interactions described by these authors were detected in the presence of cell extracts.
The transactivating capacity of ATF2 is dependent on the presence of Thr69 and Thr71, and upon phosphorylation of these residues by SAPKs the transactivating potential is strongly enhanced (Gupta et al., 1995; Livingston et al., 1995) . We show here that these two residues are also essential for the activation of ATF2 by p300. In the case of cJun, the SAPK/JNKphosphorylation sites involved in transactivation have been found to be essential for the binding of these proteins to CBP/p300, although phosphorylation does not seem to be required . For ATF2 there are several indications that Thr69 and Thr71 do not play a role in the binding to p300/CBP. Phosphorylation of Thr69 and Thr71 is not required for binding, as ATF2 does not seem to be phosphorylated on these residues in E1-transformed cells and F9 cells (Duyndam et al., 1996 and unpublished results) . Moreover, we do not observe preferential binding of hyperphosphorylated ATF2 proteins to p300/CBP after treatment of cells with arsenite (an inducer of SAPK activity). Finally, ATF2 mutant proteins in which Thr69 and Thr71 were replaced by alanines, were found to associate eciently with p300/CBP proteins in E1-transformed HER cells. Since mutation of Thr69 and Thr71 dramatically reduces the basal activity of the ATF2 N-terminus, these two residues might be essential for the interaction of ATF2 with basal transcription factors. In this respect it is interesting to note that transactivation by the cAMP-inducible transcription factor CREB seems to require interactions of CREB with both CBP (following phosphorylation of CREB on Ser133) and TAFII130 (Nakajima et al., 1997) . It might be that also in the case of ATF2 two independent protein-protein interactions are involved in transactivation. This could explain the fact that the N-terminus of ATF2 mutated at Thr69 and Thr71 is not at all activated by p300 (in spite of the fact that it can associate with p300) while this mutant is still partially activated by E1A . The latter is also found for the full length ATF2 protein: overexpression of ATF2 mutated at Thr69 and Thr71 completely inhibits the activation of the c-jun promoter by p300 (Figure 7b ), but does not appear to inhibit the activation of the c-jun promoter by E1A (data not shown). Another result of our study is the co-operative activation of the ATF2 N-terminus by p300 and E1A. The observation that promoters activated by CREB, cJun, JunB and cFos can be activated by p300/CBP and repressed by E1A, dependent on the capacity of E1A to bind to p300/CBP, was explained by the binding of E1A to p300/CBP, resulting in inhibition of its coactivator function Lundblad et al., 1995; Lee et al., 1996a) . In agreement with these observations it was found that the inhibition of various promoters by E1A could be overcome by overexpression of p300 (Eckner et al., 1994; Yuan et al., 1996; Hasegawa et al., 1997; Puri et al., 1997; Missero et al., 1995; Smits et al., 1996; Lill et al., 1997) . We found that under the assay conditions where 12S E1A inhibits the cJun-induced collagenase promoter activity, 12S E1A functionally co-operates with p300 in the activation of the ATF2 Nterminus or the c-jun promoter. This co-operative activation is independent of direct binding of p300 to E1A, since a p300 mutant defective for binding to E1A could still co-operate with E1A ( Figure 3 and data not shown). The fact that E1A has opposite eects on the p300-induced activity of CREB, cJun, JunB and cFos on the one hand, and on that of ATF2 on the other may be explained by the fact that p300 can only indirectly interact with ATF2 and this indirect interaction cannot be disrupted by the E1A protein.
For the co-operative activation of ATF2 by p300 and E1A one could then postulate a model in which 12S E1A activates ATF2 via cofactors that are dierent from the ones that are used by p300.
Finally, our results indicate that E1A does not inhibit all transcription activation eects by p300, which is actually not very surprising. The recently published knock-out studies (Yao et al., 1998) illustrate that p300 is not only required for terminal differentiation of certain cell types (Billon et al., 1996; Hasegawa et al., 1997; Puri et al., 1997) but also for cell proliferation. As E1A can induce cell proliferation, it is unlikely that E1A would inactivate all p300 properties, especially not the functions of p300 associated with proliferation. In fact, E1A might potentiate some of the functions of p300 and the activation of the ATF2 N-terminus by p300 and E1A reported here may represent such a potentiation.
Materials and methods

Plasmid constructs
The 71600/+740 c-jun and 71600/+740 c-junmjun1mjun2-Luciferase plasmids were constructed by introducing the 2.3 kb BglII fragments of p1600/+740 c-jun-CAT and p71600/+740 c-junmjun1mjun2-CAT (van Dam et al., 1993) into BglII-restricted pGL2-basic (Promega). P7517/+63 collagenase-Luciferase, 12S E1A (pJF12) and RSVc-Jun have been described (resp.: Smits et al., 1996; Schneider et al., 1987; Angel et al., 1988) . pCMV300 and pCMV300del30 (Eckner et al., 1994) were kindly provided by R Eckner (Harvard Medical School, Boston, MA, USA). For the construction of pCMVATF2 and pCMVATF2 T69+T71, the SalI ± BglII fragments of pRSVGal4wtATF2 (codons 19 ± 505; Duyndam et al., 1996) and pRSVGal4ATF2 T69+T71 (codons 19 ± 505 with threonines 69 and 71 mutated into alanines; van Dam et al., unpublished) were subcloned into PUC21 (Vieira et al., 1991) . Subsequently, BamHI ± BglII fragments were inserted into the BamHI site of pCMVNeoBamHI (Baker et al., 1990) . The RSVGal4-ATF2 N (codon 1 ± 112), RSVGal4-ATF2 N T69+T71 and RSVGal4-cJun (codon 1 ± 166) constructs have been described (Radler-Pohl et al., 1993; Duyndam et al., 1996) . pRSVGal4-ATF3 (codon 1 ± 66) and pRSVGal4-JunD (codons 1 ± 255) (Low et al., 1994) was kindly provided by KG Low (Massachusetts General Hospital, Charlestown, Massachusetts, USA). The Gal4-reporter construct 56Gal4E4-Luciferase (Flint and Jones, 1991) was kindly provided by K Livingston and N Jones, Imperial Cancer Research Fund (London, UK).
Cell culture, transient transfections and luciferase assay F9 cells were grown in F12-DMEM (1 : 1) supplemented with 10% FCS, penicillin (100 mg/ml), streptomycin (100 mg/ml) and 0.1 mM b-mercaptoethanol. Adenovirus type 5 (Ad5) E1-transformed HER cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% foetal calf serum, penicillin (100 mg/ml) and streptomycin (100 mg/ml). F9 cells and adenovirus 5 (Ad5) E1-transformed HER cells were transfected by the calciumphosphate precipitation method (Graham and van der Eb, 1973) . After a 6-h incubation period, the cells were washed and refed with culture medium. Luciferase assays were performed as described by Duyndam et al. (1996) .
Antibodies cJun-Ab-1, directed against aa. 209 ± 225 (pep-1) was purchased from Oncogene Science (New York, USA). ATF2 (sc-187) and ATF3 (sc-188) antisera, directed against 487 ± 505 and 194 ± 212, respectively, were purchased from Santa Cruz Biotechnology (California, USA). The rabbit polyclonal p300-(1) and p300-(2) antisera were raised against puri®ed, bacterial produced His-tagged proteins containing aa 91 ± 328 and aa 1834 ± 2049 of the p300 protein, respectively. In sequential immunoprecipitation assays, a CBP speci®c antiserum was found to precipitate CBP proteins after disruption of immunoprecipitates of the two p300 antisera, indicating that the two p300 antisera crossreact with CBP.
UV crosslinking and immunoprecipitation
Preparation of extracts and the synthesis of the 32 P-labelled jun2 oligonucleotide were performed as described . The double-stranded competitor oligonucleotides were obtained by annealing of 5'AGC-TAGCATTACCTCATCCC-3' and 5'-GATCGGGATGA-GGTAATGCT-3' (jun2: human promoter c-jun, position 7194 to 7179) and 5'-AGCTAGCATGAGTCAGACAC-3' and 5'-AGCTGTGTCTGACTCATGCT-3' (coli: human promoter collagenase, position 776 to 761).
For immunoprecipitation with non immune or p300 antisera, the 32 P-labelled jun2 oligonucleotide (300 fmol) was incubated with 180 mg of whole-cell extract and 15 mg poly(dl-dC) in 180 ml binding buer (10 mM HEPES pH 7.9, 60 mM KCl, 1 mM EDTA, 1 mM MgCl 2 , 4% Ficoll, 1 mM DDT, 1 mM phenyl methyl sulphonyl¯uoride (PMSF), 0.5 mM trypsin inhibitor, 1 mM leupeptin) for 30 min at room temperature. For immunoprecipitations with cJun, JunD, ATF2 or ATF3 antisera, the 32 P-labelled jun2 oligonucleotide (100 fmol) was incubated with 60 mg of whole-cell extract and 5 mg poly(dl-dC) in 60 ml binding buer for 30 min at room temperature. After a 20 min irradiation period with UV (on ice, 254 nm, 80 kJ/m 2 , the binding mixtures were diluted ®vefold in a mild buer (E1A buer: 50 mM Tris-HCl pH 7.0, 250 mM NaCl, 5 mM EDTA and 0.1% NP40) and incubated for 2 h with antisera pre-coupled to protein A-Sepharose beads at 48C. The protein-DNA complexes were centrifuged, washed three times with E1A buer, resolved by SDS ± PAGE and visualized by autoradiography. Competition was performed by incubating the extracts with a 100-fold excess of unlabelled competitor oligonucleotide for 5 min, before the addition of 32 P-labelled jun2 oligonucleotide.
Cell labelling and immunoprecipitation
Exponentially growing cell cultures were incubated with 32 S-Methionine in MEM de®cient for L-methionine for 4 h. Cells were lysed in E1A buer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA and 0.1% NP40) for 30 min after which the lysates were cleared by centrifugation. Equal amounts of supernatant were incubated for 2 h at 48C with antisera that had been pre-coupled to protein ASepharose beads for 1 h at 48C. In case of a sequential immunoprecipitation, the following procedure was carried out: washed immunocomplexes were incubated in 100 ml denaturation buer (10 mM Tris-HCl pH 8.0, 1% SDS) at 1008C for 5 min to release associated proteins. After centrifugation, the supernatants were diluted with 900 ml RIPA-1 buer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP40, 1% sodium-deoxycholate) without SDS and with 0.04% Bovine Serum Albumin. Supernatants were incubated with antisera as described above. Immunoprecipitates were resolved by SDS ± PAGE and visualized by autoradiography.
